Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXL and Intacs for Keratoconus
NCT01112072Phase 3Active, not recruiting
- Sponsor
- Cornea and Laser Eye Institute
- Start
- Apr 2010
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of riboflavin in keratoconus and corneal ectasia (2 arms), sponsored by Cornea and Laser Eye Institute. Primary endpoint: Maximum keratometry at 1 year. Started Apr 2010; status: active, not recruiting.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT01112072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01112072.